Cargando…

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

Chimeric antigen receptor (CAR) T-cells targeting CD19 mediate potent effects in relapsed/refractory pre-B cell acute lymphoblastic leukemia (B-ALL) but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed on most B-ALL and usually retained following...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fry, Terry J., Shah, Nirali N., Orentas, Rimas J., Stetler-Stevenson, Maryalice, Yuan, Constance M., Ramakrishna, Sneha, Wolters, Pamela, Martin, Staci, Delbrook, Cindy, Yates, Bonnie, Shalabi, Haneen, Fountaine, Thomas J., Shern, Jack F., Majzner, Robbie G., Stroncek, David F., Sabatino, Marianna, Feng, Yang, Dimitrov, Dimiter S., Zhang, Ling, Nguyen, Sang, Qin, Haiying, Dropulic, Boro, Lee, Daniel W., Mackall, Crystal L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774642/ https://www.ncbi.nlm.nih.gov/pubmed/29155426 http://dx.doi.org/10.1038/nm.4441

Ejemplares similares

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
por: Schneider, Dina, et al.
Publicado: (2017)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
por: Walker, Alec, et al.
Publicado: (2014)

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020)

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
por: Jackson, Zachary, et al.
Publicado: (2020)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
por: Faruqi, Aiman J., et al.
Publicado: (2022)

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
por: Richards, Rebecca M., et al.
Publicado: (2021)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
por: Maschan, Michael, et al.
Publicado: (2021)

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
por: Jacoby, Elad, et al.
Publicado: (2016)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
por: Caimi, Paolo F., et al.
Publicado: (2021)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells
por: Anthony-Gonda, Kim, et al.
Publicado: (2022)

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
por: Myers, Regina M., et al.
Publicado: (2022)

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
por: Spiegel, Jay Y., et al.
Publicado: (2021)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22
por: Sun, Zehua, et al.
Publicado: (2022)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)

c-Jun overexpression in CAR T cells induces exhaustion resistance
por: Lynn, Rachel C., et al.
Publicado: (2019)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
por: Mo, George, et al.
Publicado: (2020)

Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy
por: Shao, Lipei, et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jcseain1npfhluu8ji69b67bn8